NHS South of England Branded Medicines - Tranche A - September 2023

A Contract Award Notice
by NHS ENGLAND

Source
Contracts Finder
Type
Framework (Products)
Duration
2 year
Value
£250M
Sector
HEALTH
Published
14 Aug 2023
Delivery
01 Sep 2023 to 31 Aug 2025
Deadline
11 Apr 2023 12:00

Concepts

Location

Geochart for 1 buyers and 33 suppliers

1 buyer

33 suppliers

Description

NHS South of England Branded Medicines - Tranche A - September 2023 Offer reference number: CM/PHR/22/5676 CM/PHR/22/5676/01 - NHS Framework for South of England Branded Medicines - Tranche A. Period of framework: 1 September 2023 to 31 August 2025 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months. CM/PHR/22/5676/02 - NHS Framework for South of England Branded Medicines - Annual Tranche. Period of framework: 1 September 2023 to 31 August 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months. CM/PHR/22/5676/03 - NHS Framework Agreement for the supply of Risankizumab for the Midlands & East and North of England. Period of framework: 1 September 2023 to 29 February 2024 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 12 months.

Award Detail

1 Orifarm (Hemel Hempstead)
  • Value: £249,832,000
2 Celltrion Healthcare (Slough)
  • Value: £249,832,000
3 Sandoz (Camberley)
  • Value: £249,832,000
4 Amgen (Cambridge)
  • Value: £249,832,000
5 Glaxosmithkline (London)
  • Value: £249,832,000
6 Thornton & Ross (Huddersfield)
  • Value: £249,832,000
7 Sun Pharma (Uxbridge)
  • Value: £249,832,000
8 Accord (Barnstaple)
  • Value: £249,832,000
9 Roche Products (Welwyn Garden City)
  • Value: £249,832,000
10 Merck Sharpe & Dohme (London)
  • Value: £249,832,000
11 Teva (Castleford)
  • Value: £249,832,000
12 Astrazeneca (London)
  • Value: £249,832,000
13 Zentiva Pharma (London)
  • Value: £249,832,000
14 Abbvie (Maidenhead)
  • Value: £249,832,000
15 Pharmacosmos (Kings Road Reading)
  • Value: £249,832,000
16 Pfizer (Sandwich)
  • Value: £249,832,000
17 Aventis Pharma (Reading)
  • Value: £249,832,000
18 Janssen Cilag (High Wycombe)
  • Value: £249,832,000
19 Eli Lilly (Hants)
  • Value: £249,832,000
20 Takeda (London)
  • Value: £249,832,000
21 Merck Serono (Feltham)
  • Value: £249,832,000
22 Organon Pharmaceuticals (London)
  • Value: £249,832,000
23 Vifor Pharma (London)
  • Value: £249,832,000
24 Almirall (Uxbridge)
  • Value: £249,832,000
25 Gedeon Richter (London)
  • Value: £249,832,000
26 Galapagos Biotech (Cambridge)
  • Value: £249,832,000
27 Chugai Pharma (London)
  • Value: £249,832,000
28 Novo Nordisk (Gatwick)
  • Value: £249,832,000
29 Novartis Pharmaceuticals (London)
  • Value: £249,832,000
30 Merz (Hemel Hempstead)
  • Value: £249,832,000
31 Sobi Swedish Orphan Biovitrum (Great Abington)
  • Value: £249,832,000
32 Ucb Pharma (Slough)
  • Value: £249,832,000
33 Napp Pharmaceuticals (Cambridge)
  • Value: £249,832,000

CPV Codes

  • 33600000 - Pharmaceutical products

Indicators

  • Contract is suitable for SMEs.

Other Information

Transparency Documents - SOFE - 5676-02 Transparency Documents - SOFE - 5676-02.pdf 03 - Framework Agreement and Terms and Conditions CM_PHR_22_5676 03 - Framework Agreement and Terms and Conditions CM_PHR_22_5676.pdf Document No. 10 - Pharmacy Purchasing Points List CM_PHR_22_5676 copy Document No. 10 - Pharmacy Purchasing Points List CM_PHR_22_5676 copy.xlsx FTS-006780 PUBLISHED Opportunity Notice - CM_PHR_22_5676 SOFE Tranche A copy FTS-006780 PUBLISHED Opportunity Notice - CM_PHR_22_5676 SOFE Tranche A copy.pdf Transparency Documents - SOFE - 5676-01 Transparency Documents - SOFE - 5676-01.pdf Parties Appointed to the framework CM-PHR-22-56-5676 Parties Appointed to the framework CM-PHR-22-56-5676.docx

Reference

Domains